MARKET WIREBenzinga • 4d ago
'Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying' - NY Timeshttps://www.nytimes.com/2026/10/28/us/politics/trump-opioid-kratom.html
Why LTGO Stock slipped -1.83% Today — RQD Quant Desk Flash
$15.54 -1.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $15.46
Latigo Biotherapeutics Inc. (LTGO) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.03B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LTGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $15.54 (-1.83% 1D, market cap $1.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LTGO ranks #279 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LTGO compare to SVRA and MLTX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SVRA (Savara Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and MLTX (MoonLake Immunotherapeutics (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LTGO?
▼
Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $15.46 (-0.52%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE-1.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LTGO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY LTGO SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (27% of score)
FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 38 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$16.00-12.5% Next Q
63
Q2 (-2Q)Grade C$14.00+7.3% Next Q
60
Q3 (-1Q)Grade C$15.02+3.5% Next Q
58
CurrentGrade D+$15.54-0.5% Hist 90D α
55
Trajectory: C+ (63) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the LTGO Bull Thesis Could Fail
Even with a 55/100 (D+) score, LTGO faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($18.92) or 200D SMA ($19.03) invalidates the momentum regime and cuts Target Base ($15.33) toward Bear Floor ($11.96).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LTGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LTGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LTGO Stock slipped -1.83% Today — RQD Quant Desk Flash
Latigo Biotherapeutics Inc. (LTGO) slipped -1.83% to $15.54, trading at 16% of its 52-week range ($13.5 – $25.93). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($13.5 – $25.93) with RSI-14 at 38 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $15.54 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $28.8M annual free cash flow.
Live LTGO Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LTGO)
- ✓Walkthrough of LTGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LTGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.85%▼ DESCENDING CHANNEL
2026-10-30O $15.65H $15.70L $13.66C $15.54VOL 216.2K
RES: $22.54SUP: $11.22SMA50: $18.92SMA200: $19.03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LTGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LTGO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LTGO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LTGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LTGO)
Health Care Rank #279 of 1016
⚔️ SVRA vs LTGO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LTGO vs. SVRA, MLTX, JANX, RIGL)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Latigo Biotherapeutics Inc. (LTGO) ranks #279 by composite RQD confidence (55/100, grade D+) and #358 by equity capitalization ($1.03B). Within this direct 5-issuer industry benchmark cohort, LTGO leads on earnings valuation at N/A trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with LTGO at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LTGO
ACTIVE
Latigo Biotherapeutics Inc. | D+ | 55/100 | — | — | — | -1.83% | $1.03B | Benchmark Subject |
| SVRA Savara Inc. | D- | 43/100 | — | — | -35.0% | -1.39% | $1.02B | /svra-vs-ltgo → |
| MLTX MoonLake Immunotherapeutics (Class A) | D | 46/100 | — | — | -35.0% | +2.11% | $1.07B | /mltx-vs-ltgo → |
| JANX Janux Therapeutics Inc. | E | 33/100 | — | — | -13.8% | -1.22% | $1.09B | /janx-vs-ltgo → |
| RIGL Rigel Pharmaceuticals Inc. | B | 74/100 | — | 93.3% | 28.2% | +1.40% | $961.1M | /rigl-vs-ltgo → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002056611In its most recent audited fiscal period (FY2025, filed 2025-12-31), Latigo Biotherapeutics Inc. (LTGO) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LTGO closed FY2025 with $75.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $75.5M | — |
3. LTGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $15.54 (-1.83% 1D, market cap $1.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LTGO ranks #279 in composite RQD confidence.
How does LTGO compare to SVRA and MLTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SVRA (Savara Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and MLTX (MoonLake Immunotherapeutics (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LTGO?
Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LTGO trading relative to its 50-day, 200-day, and 52-week technical levels?
LTGO last traded at $15.54 (-1.83% on volume of 141,665 shares), positioning the stock -17.86% below its 50-day simple moving average ($18.92) and -18.34% below its 200-day simple moving average ($19.03). Across its 52-week range of $13.50 to $25.93, LTGO sits at the 16.4% percentile with a 14-day RSI of 38.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.60 to $17.48).
LTGO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LTGO stock moving today?
Why LTGO Stock slipped -1.83% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.